PPARG and early-onset autosomal dominant Alzheimer disease: New-generation TZDs with decreased affinity for PPARγ maintain the therapeutic benefit (36, 37) and have been considered in clinical trials for MASH (17, 38) and Alzheimer’s disease (39).